• Eli Lilly and Co., of Indianapolis, and Kowa Pharmaceuticals America Inc., of Montgomery, Ala., reported results from the PREVAIL (Pitavastatin compaREd with praVAstatin in Lowering LDL-C in the U.S.) study, which showed that Livalo (pitavastatin) 4 mg had superior LDL-C reduction compared with pravastatin 40 mg after 12 weeks of therapy. Data for secondary endpoints showed that Livalo reduced apoliprotein B, non-HDL-C and total cholesterol compared with pravastatin and improved high-density lipoprotein cholesterol and triglycerides. Those results were presented at the National Lipid Association's Scientific Sessions in Scottsdale, Ariz.
To read more on related topics, click on one of the words below.